{"filings":[{"id":2105637,"accession_number":"0001493152-26-036331","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2026-08-06T20:02:03+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q2 revenue record $6M (+36% YoY); net income $1.2M includes $0.6M tariff refund","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $6.0M (record), up 36% YoY; core programmatic revenue grew 27%.","Net income $1.2M vs $0.2M; includes $0.6M one-time tariff refund; adjusted EBITDA $1.3M vs $0.4M.","Gross margin improved to 67% from 63%, aided by tariff refund; six-month revenue $11.2M (+21%).","Cash $4.7M, debt free; CEO cites new product launches (microplastics, PFAS) and Russell Microcap inclusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1038000,"accession_number":"0001493152-26-028539","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2026-06-12T21:43:53+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nephros posts updated 2026 corporate presentation; no material details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted an updated 2026 Corporate Presentation on its website on June 12, 2026.","Presentation included as Exhibit 99.1 but specific content not available in this filing.","No financial data, guidance, or operational metrics were disclosed in the 8-K text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91719,"accession_number":"0001493152-26-021734","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q1 net revenue up 7% to $5.2M; net income falls to $140K; tariffs hit margins","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $5.2M (+7% YoY); programmatic revenue up 23% YoY.","Net income of $140K vs $558K in Q1 2025; adjusted EBITDA $206K vs $667K.","Gross margin fell to 57% from 65%, pressured by ~$200K in tariffs and Euro strength.","Commercial mix shift (ice machines, fountains) expands addressable market but lowers near-term margins.","Cash $4.0M, no debt; conference call at 4:30pm ET today."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":5212000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101984,"accession_number":"0001493152-26-013189","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nephros posts updated 2026 corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing includes an updated corporate presentation posted on company website on March 27, 2026.","Presentation is furnished as Exhibit 99.1; no specific financial or operational updates provided in filing.","No earnings, M&A, leadership changes, or other material events referenced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118326,"accession_number":"0001493152-25-025155","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Nephros signs exclusive license & supply deal with Medica; min purchases €4.98M-€6.3M/yr through 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Replaces prior Dec 2023 License & Supply Agreement with Medica; that agreement terminated.","Nephros receives exclusive right to market & sell Products using Medica's Medisulfone ultrafiltration tech.","Minimum annual purchases from Medica: €4.976M (2026), €5.349M (2027), €5.750M (2028), €6.000M (2029), €6.300M (2030).","Term through Dec 31, 2030; Nephros may terminate for convenience with 90 days' notice; Medica may terminate for uncured monetary default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134767,"accession_number":"0001641172-25-022978","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q2 net rev $4.4M (+36% YoY); net income $237k vs loss $289k; 3rd consecutive profitable quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $4.4M, up 36% YoY from $3.3M; net income $237k vs net loss $289k.","Adjusted EBITDA $355k vs $(133k); gross margin improved to 63% from 59%.","Six-month net income $795k vs loss $458k; revenue $9.3M (+37% YoY).","Programmatic sales all-time high; largest dialysis filtration PO in company history.","Cash $5.1M, debt-free; active-site counts at all-time highs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":9296000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151683,"accession_number":"0001641172-25-015250","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nephros shareholders elect Lisa Nettis to board, ratify auditor, approve exec comp at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lisa Nettis elected to three-year term with 6,066,124 votes for, 84,178 withheld.","Baker Tilly US, LLP ratified as independent auditor for FY2025 with 8,663,982 for, 137,516 against.","Advisory vote on named executive officer compensation passed with 6,078,954 for, 41,762 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151682,"accession_number":"0001641172-25-009262","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q1 2025 revenue $4.9M (+38% YoY), net income $558K, adjusted EBITDA $667K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $4.9M, up 38% from $3.5M in Q1 2024; core programmatic revenue grew 23%.","Net income of $558,000 vs net loss of ($169,000) in Q1 2024; adjusted EBITDA $667,000 vs ($95,000).","Gross margin improved to 65% from 62%; record active sites of 1,600.","Cash and equivalents $4.1M, debt-free.","Management notes Q1 included elevated emergency business not expected to persist; tariff uncertainties but strong positioning."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":4877000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151681,"accession_number":"0001641172-25-006427","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Alisa Lask will not stand for re-election at Nephros annual meeting on June 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alisa Lask notified the board on April 23, 2025, that she will not stand for re-election.","Her term on the board will expire at the 2025 annual meeting scheduled for June 16, 2025.","Lask's decision was not due to any disagreement with Nephros on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151680,"accession_number":"0001641172-25-001940","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nephros posts updated 2024 corporate presentation on website; no material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing announces posting of updated corporate presentation on company website.","No new financial data, guidance, or operational updates included in the 8-K.","Presentation content is not summarized; investors must review directly.","No earnings, M&A, leadership, or other material events reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170533,"accession_number":"0001493152-25-009390","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros reports first annual net income; Q4 revenue up 19% YoY to $3.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $74K for FY2024 vs net loss of $1.6M in 2023; first annual profit in company history.","Q4 net revenue $3.9M (+19% YoY); full-year revenue flat at $14.2M with core programmatic up 9% offset by emergency decline.","Gross margin improved to 62% for year (vs 59%) due to better supplier terms; SG&A down 14%.","Added nearly 600 new customer sites (~$2M sales); launched 20\" HydraGuard Ultrafilter for sterile processing market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170532,"accession_number":"0001493152-25-009035","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nephros CFO Krandel gets two stock options, bonus target raised to 30%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amendment to CFO Judith Krandel's letter agreement grants options for 54,359 and 58,961 shares under 2024 Equity Incentive Plan.","First option vests 25% on first anniversary, then quarterly over 3 years; second vests upon closing a strategic transaction adding ≥$4M annual revenue.","Annual performance bonus target increased to 30% of base salary; options accelerate upon termination without cause.","Grant date is 3rd business day after filing 2024 10-K; exercise price equals closing price on grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187527,"accession_number":"0001493152-24-045135","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros posts Q3 net income of $0.2M, first profitable quarter; revenue $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $3.5M, down 6% YoY but up 8% from Q2 2024.","Net income $0.2M vs net loss $0.2M in Q3 2023; first profitable quarter.","Adjusted EBITDA $295K vs $11K; gross margin improved to 61% from 59%.","Cash $2.5M as of Sep 30, 2024, down from $4.3M at Dec 31, 2023.","CEO cites South Central region underperformance and slower ordering from large accounts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":10292000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204014,"accession_number":"0001493152-24-033872","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nephros posts updated 2024 corporate presentation; no financial details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated 2024 Corporate Presentation made available on company website on August 26, 2024.","Presentation furnished as exhibit; no specific financial or operational metrics disclosed in the filing.","No changes to guidance, revenue, or earnings were announced in connection with this update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220706,"accession_number":"0001493152-24-021342","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Nephros stockholders approve 2024 Equity Incentive Plan authorizing 2,616,875 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan adds 900,000 new shares plus prior plan reserve and returning shares; total shares authorized 2,616,875.","Stockholders elected directors Arthur H. Amron (6,860,037 for) and Oliver Spandow (6,690,864 for).","Ratified Baker Tilly US, LLP as independent auditor for FY2024 (8,545,420 for, 21,330 against).","Advisory say-on-pay approved with 6,832,340 for, 62,907 against.","Prior plan no longer available for new grants; all outstanding awards remain subject to prior terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220705,"accession_number":"0001493152-24-018435","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q1 revenue down 5% to $3.5M; net loss narrows to $0.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $3.5M, down 5% YoY, but programmatic (recurring non-ER) business grew 12% YoY.","Net loss improved to $0.2M from $0.3M loss in Q1 2023.","Gross margin expanded to 62% from 57%, driven by lower shipping costs and better supplier terms.","Adjusted EBITDA fell to ($95,000) from $147,000; cash decreased to $3.6M.","Launched online filter tracker; exploring nano/microplastic filtration capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":3522000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220704,"accession_number":"0001493152-24-017355","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nephros furnishes corporate presentation at MicroCap showcase; no material new info","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing indicates presentation at Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024.","No specific financial or operational updates are provided in the filing or exhibit.","This is a routine disclosure of investor materials; no guidance changes or material events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240320,"accession_number":"0001493152-24-009216","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros FY2023 revenue up 43% to $14.2M; net loss narrows to $1.6M from $4.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year net revenue from continuing ops $14.2M, up 43% YoY; Q4 revenue $3.3M, up 27%.","Net loss from continuing ops improved 63% to ($1.6M) for FY2023 vs ($4.3M) in 2022.","Adjusted EBITDA loss from continuing ops narrowed to ($0.1M) for FY2023, an improvement of 97%.","Cash and cash equivalents $4.3M at Dec 31, 2023; company remains debt-free.","CEO cites regulatory tailwinds from new water safety standards like ASHRAE 514 driving growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257821,"accession_number":"0001493152-23-039516","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nephros appoints Judy Krandel as CFO; Andrew Astor resigns effective Nov 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Judy Krandel appointed CFO effective Nov 1, 2023, replacing Andrew Astor.","Krandel receives base salary $140k, 25% bonus target, and inducement option for 122,524 shares at $1.71.","Option vests 25% on first anniversary, then quarterly over 4 years.","Astor remains through Dec 31, 2023 to assist transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275175,"accession_number":"0001493152-23-027357","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q2 2023 revenue $3.5M (+24% YoY); net loss narrows to $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $3.5M, up 24% from $2.9M in Q2 2022.","Net loss from continuing ops narrowed to $0.4M from $0.7M; adjusted EBITDA loss $0.2M vs $0.4M.","Gross margins improved to 59% from 49%; active customer sites up 6% to 1,427.","Cash and equivalents $4.1M as of June 30, 2023; maintained positive cash flow.","Cost of goods sold flat at $1.5M; SG&A increased to $2.2M from $1.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":7242000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292600,"accession_number":"0001493152-23-019798","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nephros annual meeting: Harris elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joseph Harris elected director with 5,333,628 votes for (term expires 2026).","Baker Tilly US, LLP ratified as auditor for FY2023: 8,622,127 for, 9,252 against.","Non-binding advisory vote on NEO compensation passed: 5,309,669 for, 885,868 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292599,"accession_number":"0001493152-23-016374","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nephros appoints Robert Banks as President & CEO; Andy Astor remains interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Banks named President & CEO effective after Q1 2023 10-Q filing; also appointed to Board.","Andy Astor resigns as President & CEO but stays as interim CFO and advisor; departure not due to disagreement.","Banks receives $350K base salary, potential increases to $400K/$450K at $15M/$20M revenue milestones.","Banks granted 357,165 stock options at $1.44 per share, vesting over 4 years.","Company highlights 40% YoY base revenue growth and early cash-flow breakeven in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292598,"accession_number":"0001493152-23-010797","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros preliminary Q1 net revenue $3.7M (+69% YoY); expects break-even cash flow from ops","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue approximately $3.7 million for Q1 2023, a 69% increase over Q1 2022.","Base revenue (excluding a large emergency order) expected to exceed $3.0 million, up about 40% YoY.","Expects cash flows from water filtration operations to be at least break-even in Q1; on track for consistent positive cash flows by mid-2023.","Ended Q1 with $3.8 million cash on a consolidated basis, compared to $3.6 million at Dec 31, 2022.","Full Q1 2023 results to be announced May 10, 2023 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":3697000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313258,"accession_number":"0001493152-23-007004","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros reports FY2022 net revenue $10M; net loss widens to $4.3M; subsidiary SRP winding down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue from continuing operations: $10.0M in FY2022 (-2% YoY); Q4 $2.6M (-6% YoY).","Net loss from continuing operations: $4.3M in FY2022 vs $2.8M loss in 2021; Q4 loss $0.7M flat.","Gross margins improved to 59% in Q4 (vs 54% prior year); full-year margins 47% (vs 55%).","Majority-owned subsidiary SRP to wind down after failing to find strategic partner; expects cessation in Q2 2023.","Cash and equivalents $3.6M at Dec 31, 2022; targeting cash flow breakeven by mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313257,"accession_number":"0001493152-23-003465","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nephros director Thomas Gwydir resigns; Alisa Lask appointed to Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Gwydir resigned from the Board effective Feb 1, 2023; no disagreement with company.","Alisa Lask appointed to Audit Committee on Feb 2, 2023 to fill the vacancy.","Resignation and appointment are routine governance actions; no material impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313256,"accession_number":"0001493152-23-001134","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros reports preliminary Q4 revenue of $2.6M, FY2022 revenue of $10.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net revenue ~$2.6M, down 6% YoY but up 6% sequentially.","Full-year 2022 net revenue ~$10.0M, a 2% decrease from 2021.","Record Active Customer Sites of 1,394 at Q4 end; an all-time high.","Cash balance ~$3.6M; H2 2022 net cash flow improved to -$0.5M from -$2.9M in H1.","Formal Q4 and FY2022 earnings call scheduled for March 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":9975000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331784,"accession_number":"0001493152-22-033098","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["2.01","1.01","9.01"],"status":"ready","headline":"Nephros closes sale of Pathogen Detection Systems business to BWSI, LLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closing occurred Nov 15, 2022; BWSI made nominal cash payment and assumed certain liabilities.","Annual royalty of a specified % of gross margin from PDS products for 7 years starting 2023.","Pro forma for 9M 2022: net loss attributable to Nephros improved from $6.464M to $3.764M.","Pro forma for FY 2021: net loss attributable to Nephros improved from $4.107M to $3.024M.","PDS Business classified as discontinued operations; assets/liabilities removed from balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331783,"accession_number":"0001493152-22-030207","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q3 net revenue $2.4M (-7% YoY); net loss widens to $1.3M; sells PDS business","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue from continuing operations $2.4M, down 7% vs Q3 2021; net loss $1.3M vs $0.8M.","Adjusted EBITDA loss from continuing operations -$0.3M, improving from -$0.4M in prior year.","Active Customer Sites grew 18% YoY to a record 1,391; price pull-ahead in Q2 hurt revenue.","Sold Pathogen Detection Systems (PDS) business; reduces quarterly expenses by ~$300K.","Cash and equivalents $3.9M at Sept 30, 2022; management targets positive cash flow by mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":7417000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331782,"accession_number":"0001493152-22-028035","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Nephros sells Pathogen Detection Systems business, reports prelim Q3 revenue ~$2.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Entered definitive agreement to sell Pathogen Detection Systems (PDS) business to BWSI; expected close mid-November 2022.","Sale includes seven-year earn-out based on a portion of gross profits from PDS products.","Preliminary Q3 2022 revenue expected ~$2.5M; Active Customer Sites up 18% YoY to 1,391.","Cash position ~$3.9M at quarter end; sale expected to reduce expenses by ~$350k per quarter.","Company aims for positive net cash flow by mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349264,"accession_number":"0001493152-22-025393","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nephros appoints Joe Harris to Board of Directors, effective September 6, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joe Harris appointed as Class III Director, term expiring at 2023 Annual Meeting.","Harris will serve on Audit and Compensation Committees.","Standard non-employee director compensation: $20,000 annual retainer, $1,500 per board meeting.","Granted option to purchase 13,115 shares at $1.25/share, vesting over 3 years.","Harris brings 20+ years sales management experience; currently Midwest Sales Director at Murj."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349263,"accession_number":"0001493152-22-023841","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-08-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nephros Chief Commercial Officer Wes Lobo resigns effective September 30, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wes Lobo notified Nephros of his resignation as Chief Commercial Officer on August 17, 2022.","His resignation is effective no later than September 30, 2022.","No successor or interim replacement has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349262,"accession_number":"0001493152-22-021892","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q2 revenue up 27% to $2.9M; net loss flat at $1.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $2.9M (+27% YoY); water filtration segment $2.8M (+30% YoY).","Net loss $1.1M flat YoY; Adjusted EBITDA ($0.7M) vs ($0.8M) prior year.","Active Customer Sites hit record 1,349 (+21% YoY, +6% QoQ).","Gross margin fell to 47% from 56%; cost of goods sold rose 54%.","Targeting positive cash flow by mid-2023 via price increases, headcount cuts, SKU reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":5071000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349261,"accession_number":"0001493152-22-018632","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-07-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros prelim Q2 revenue $2.9M, up 27% YoY; expects positive net cash flow in 12 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 preliminary net revenue ~$2.9M, a 27% increase from $2.3M in Q2 2021.","Active customer sites grew 21% YoY to 1,349, adding 232 sites in trailing 12 months.","Expense management plan includes headcount reductions and facility consolidations; company projects positive net cash flow within 12 months.","Ended Q2 with approximately $4.2M in cash on a consolidated basis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":5071000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366159,"accession_number":"0001493152-22-014596","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nephros shareholders elect Astor and Lask as directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At May 19, 2022 annual meeting, Andrew Astor and Alisa Lask elected to three-year board terms (6.2M for each; 2.3M broker non-votes).","Ratification of Baker Tilly US, LLP as independent auditor for FY2022 passed with 8,637,438 for, 17,548 against, 1,177 abstain.","Advisory (non-binding) approval of named executive officer compensation passed with 6,093,819 for, 216,653 against, 12,642 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366158,"accession_number":"0001493152-22-014190","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nephros receives FDA 510(k) clearance for second-generation HDF Assist Module for hemodiafiltration therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["First and only FDA-cleared device in the US to provide hemodiafiltration therapy to ESRD patients.","Enables existing hemodialysis machines to perform HDF without costly new equipment.","Majority-owned subsidiary Specialty Renal Products to pilot device in select clinics.","No financial impact or revenue guidance change disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366157,"accession_number":"0001493152-22-012079","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q1 revenue falls 20% YoY to $2.2M; withdraws 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.0M vs $0.5M in Q1 2021; adjusted EBITDA -$1.5M.","Active customer sites rose 17% YoY to 1,276, a record.","Gross margin dropped to 47% from 58% due to higher shipping costs and inflation.","Cash and cash equivalents at $5.4M as of March 31, 2022.","Company withdrawing 2022 revenue guidance citing higher volatility in recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2187000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385646,"accession_number":"0001493152-22-005242","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros FY2021 revenue $10.4M (+22% YoY); net loss narrows to $3.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year revenue $10.4M, up 22% from $8.6M in 2020; Q4 revenue $2.8M, up 18%.","Full-year net loss ($3.9M) improved 15% from ($4.5M); Adjusted EBITDA ($2.6M) improved 29%.","Q4 water filtration segment revenue $2.7M (+16%); operating loss ($0.7M).","Reaffirms FY2022 revenue guidance of $13.0-13.5M, representing 25-30% growth.","Cash and cash equivalents $7.0M as of Dec 31, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":10404000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385645,"accession_number":"0001493152-22-001104","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2022-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Nephros reports record FY2021 revenue of $10.4M, guides FY2022 $13-13.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2021 net revenue $10.4M (+21% YoY); Q4 revenue $2.8M (+18% YoY).","Issued FY2022 revenue guidance of $13.0M to $13.5M, representing 25-30% growth.","Ended Q4 2021 with ~$7M cash; reinstated revenue guidance practice.","Pathogen Detection Systems revenue $188k in 2021; expects >200% growth in 2022.","Subsidiary SRP received FDA info request for HDF Assist; expects 510(k) clearance H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":10404000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403536,"accession_number":"0001493152-21-030449","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2021-12-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Nephros changes auditor from MFA to Baker Tilly after firm combination","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["MFA resigned as auditor on Dec 2, 2021; Audit Committee approved Baker Tilly as replacement.","No disagreements with MFA on accounting principles or audit scope during 2019, 2020, or interim period.","MFA's reports for fiscal years 2019 and 2020 contained no adverse opinion or qualification.","Company did not consult Baker Tilly before engagement on accounting or audit matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403535,"accession_number":"0001493152-21-025001","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2021-10-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros prelim Q3 2021 net revenue ~$2.6M (+24% YoY); YTD record $7.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary net revenue ~$2.6M for Q3 2021, up 24% YoY.","Year-to-date revenue ~$7.6M, highest in company history (+22% vs 2020).","Third consecutive quarter of ~25% average YoY growth.","Pathogen Detection Systems segment contributed nearly $60K in Q3 revenue.","Cash ~$7.3M at quarter end; full results expected Nov 4, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":7639000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422495,"accession_number":"0001493152-21-021834","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2021-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nephros appoints Wes Lobo as Chief Commercial Officer effective Sept 1, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wes Lobo promoted from Chief Marketing Officer to Chief Commercial Officer.","He joined Nephros in February 2021 as CMO.","New role includes sales, marketing, business development, product management, and customer service.","CEO Andy Astor cited Lobo's strategic and operational value in the expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422494,"accession_number":"0001493152-21-018731","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros Q2 revenue $2.3M (+44% YoY); net loss improves 35%; acquires GenArraytion, HDF module filed to FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $2.3M (+44% YoY); net loss improved 35% to $1.1M; adjusted EBITDA improved 46% to ($0.8M).","Water filtration segment rev $2.2M (+40% YoY); gross margin 56%; management expects 55-60%.","Acquired GenArraytion, Inc. in July 2021 to expand PCR testing and pathogen detection capabilities.","Filed FDA 510(k) for second-generation HDF Assist Module; anticipates clearance later this year for limited commercial launch.","Cash and equivalents of $8.3M as of June 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":5002000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422493,"accession_number":"0001493152-21-016611","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2021-07-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Nephros acquires GenArraytion for $1.2M in stock; gains PCR pathogen detection tech","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of $1.2M paid via 123,981 shares of Nephros common stock.","50% of shares subject to forfeiture until intellectual property transition services completed.","Nephros to pay royalties on net sales of GenArraytion products over five years.","Registration statement covering issued shares must be filed within 60 days.","GenArraytion CEO Dr. Schaudies partners with Nephros VP Dr. Smith on product integration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422492,"accession_number":"0001493152-21-016427","cik":1196298,"company_name":"NEPHROS INC","ticker":"NEPH","form_type":"8-K","filed_at":"2021-07-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nephros reports preliminary Q2 2021 revenue $2.2M (+40% YoY); submits HDF product for FDA 510(k) clearance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2021 net revenue ~$2.2M, >40% year-over-year increase.","Six-month revenue >$5M, up 20% vs same periods in 2020 and 2019.","Subsidiary SRP submitted HDF Assist Module for FDA 510(k) clearance; commercial launch planned at limited dialysis clinics.","Pathogen Detection Systems segment generated >$50k in Q2 from on-site testing services.","Consolidated cash at quarter end ~$8.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":5002000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39626391.001390815,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}